CSIMarket Company Name, Ticker, Competitors, else..
 
Dogwood Therapeutics inc   (NASDAQ: DWTX)
 
Price: $1.3600 $-0.07 -4.895%
Day's High: $1.5210000276565552 Week Perf: -15 %
Day's Low: $ 1.34 30 Day Perf: -48.87 %
Volume (M): 46,396 52 Wk High: $ 9.50
Volume (M$): $ 0 52 Wk Avg: $3.14
Open: $1.44 52 Wk Low: $1.28



 Market Capitalization (Millions $) 46
 Shares Outstanding (Millions) 34
 Employees 8
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a pre-revenue, development-stage biopharmaceutical firm focused on developing medicines to treat pain and neuropathy, specifically chronic neuropathic pain and chemotherapy-induced neuropathic pain (CINP). Its lead product candidate, Halneuron®, is a proprietary non-opioid analgesic in late-stage clinical development that modulates the Na v 1.7 sodium channel to reduce pain signals. Halneuron® has the potential to be the first FDA-approved treatment for CINP.


   Company Address: 44 Milton Avenue Alpharetta 30009 GA
   Company Phone Number: 620-8655   Stock Exchange / Ticker: NASDAQ DWTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
XFOR   -15.92%    
• View Complete Report
   



Clinical Study

In an important development in the fight against chemotherapy-induced neuropathy (CINP), Dogwoo...

Published Tue, Jan 21 2025 2:46 PM UTC

Title : Advances in Chemotherapy-Induced Neuropathy Treatment: Dogwood Therapeutics Initiates Phase 2b Trial for Halneuron:In an important development in the fight against chemotherapy-induced neuropathy (CINP), Dogwood Therapeutics Inc. has announced the commencement of patient dosing in its Phase 2b clinical trial evaluating Halneuron. The trial is set to begin in the firs...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.68
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.4
Working Capital Ratio 3.99
Leverage Ratio (MRQ) 0.18
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -9.2 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.28 $
Book Value 2 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -4,505,161
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.